Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by Marshall Wace LLP

Marshall Wace LLP decreased its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 47.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,921 shares of the company's stock after selling 38,203 shares during the period. Marshall Wace LLP owned about 0.06% of Trevi Therapeutics worth $177,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. increased its position in shares of Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after purchasing an additional 2,894 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Trevi Therapeutics in the 4th quarter worth about $49,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Trevi Therapeutics in the 4th quarter worth about $67,000. Jump Financial LLC bought a new stake in shares of Trevi Therapeutics in the 4th quarter worth about $89,000. Finally, Invesco Ltd. increased its position in shares of Trevi Therapeutics by 21.2% in the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company's stock worth $97,000 after purchasing an additional 4,133 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Oppenheimer boosted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. B. Riley reissued a "buy" rating and issued a $20.00 target price (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. D. Boral Capital reissued a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and set a $12.50 price objective on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Finally, Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the company from $9.00 to $29.00 in a research report on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $17.56.

Insiders Place Their Bets

In other news, CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. This represents a 2.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares of the company's stock, valued at approximately $519,075. This represents a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.37% of the stock is owned by insiders.

Trevi Therapeutics Stock Performance

NASDAQ TRVI remained flat at $6.60 on Friday. 1,429,963 shares of the company's stock traded hands, compared to its average volume of 1,168,524. Trevi Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $7.39. The stock has a market cap of $659.29 million, a PE ratio of -15.00 and a beta of 0.62. The firm's 50 day simple moving average is $6.15 and its 200-day simple moving average is $4.54.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04. On average, equities analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.